Aclaris Therapeutics, Inc. (ACRS)
4.39
-0.02
(-0.45%)
USD |
NASDAQ |
Oct 02, 16:00
4.395
0.00 (0.00%)
After-Hours: 20:00
Aclaris Therapeutics Enterprise Value : 524.12M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 524.12M |
| October 01, 2026 | 526.92M |
| September 30, 2026 | 645.77M |
| September 29, 2026 | 648.57M |
| September 28, 2026 | 669.54M |
| September 25, 2026 | 630.39M |
| September 24, 2026 | 662.55M |
| September 23, 2026 | 645.77M |
| September 22, 2026 | 710.09M |
| September 21, 2026 | 689.12M |
| September 18, 2026 | 679.33M |
| September 17, 2026 | 665.35M |
| September 16, 2026 | 654.16M |
| September 15, 2026 | 682.82M |
| September 14, 2026 | 698.90M |
| September 11, 2026 | 654.16M |
| September 10, 2026 | 680.03M |
| September 09, 2026 | 687.72M |
| September 08, 2026 | 757.63M |
| September 04, 2026 | 773.01M |
| September 03, 2026 | 742.25M |
| September 02, 2026 | 774.41M |
| September 01, 2026 | 752.04M |
| August 31, 2026 | 756.23M |
| August 28, 2026 | 750.64M |
| Date | Value |
|---|---|
| August 27, 2026 | 771.61M |
| August 26, 2026 | 775.81M |
| August 25, 2026 | 824.05M |
| August 24, 2026 | 792.59M |
| August 21, 2026 | 806.57M |
| August 20, 2026 | 795.38M |
| August 19, 2026 | 810.76M |
| August 18, 2026 | 791.89M |
| August 17, 2026 | 738.05M |
| August 14, 2026 | 718.48M |
| August 13, 2026 | 729.66M |
| August 12, 2026 | 726.87M |
| August 11, 2026 | 738.05M |
| August 10, 2026 | 735.26M |
| August 07, 2026 | 736.66M |
| August 06, 2026 | 761.82M |
| August 05, 2026 | 799.58M |
| August 04, 2026 | 746.44M |
| August 03, 2026 | 683.52M |
| July 31, 2026 | 637.38M |
| July 30, 2026 | 654.16M |
| July 29, 2026 | 626.19M |
| July 28, 2026 | 655.56M |
| July 27, 2026 | 661.15M |
| July 24, 2026 | 641.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Corcept Therapeutics, Inc. | 12.24B |
| Xeris Biopharma Holdings, Inc. | 1.744B |
| Alumis, Inc. | 414.40M |
| ANI Pharmaceuticals, Inc. | 1.893B |
| Veru, Inc. | 19.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.50M |
| Revenue (Quarterly) | 1.629M |
| Total Expenses (Quarterly) | 23.13M |
| EPS Diluted (Quarterly) | -0.1507 |
| Gross Profit Margin (Quarterly) | 10.80% |
| Profit Margin (Quarterly) | -1.32K% |
| Earnings Yield | -13.33% |
| Normalized Earnings Yield | -13.23 |